KCAS Bio will be attending the 17th Open Scientific EIP (European Immunogenicity Platform) Symposium, taking place in Lisbon, Portugal, from March 16-19, 2026. This event brings together global leaders in immunogenicity to share insights, exchange ideas, and drive innovation in the development of biologics and biotherapeutics. We are excited to join the conversation and showcase how our bioanalytical expertise supports breakthroughs in immunogenicity research.
Addressing Immunogenicity in Biologic Development
Immunogenicity remains central to the safety and success of biologics. KCAS Bio delivers integrated bioanalytical strategies for immunogenicity risk assessment, including anti-drug antibody testing, neutralizing antibody assays, and biomarker analysis, all aligned with regulatory expectations. We work closely with sponsors to design fit-for-purpose approaches that generate reliable data and support confident decision-making from early research through the clinic. Our participation in the EIP Symposium reflects our ongoing commitment to advancing robust immunogenicity science and supporting the development of next-generation biotherapeutics that benefit patients worldwide.
Let’s Meet at the EIP Symposium
KCAS Bio is honored to be part of this collaborative environment and looks forward to engaging in discussions that shape the future of immunogenicity research. KCAS Bio invites you to connect with us at the 17th Open Scientific EIP Symposium in Lisbon. Our team of experts is looking forward to discussing how our bioanalytical services can support your immunogenicity studies and biotherapeutic development efforts. Contact us today to schedule a meeting during the symposium and learn how we can help advance your project. Together, we aim to drive meaningful progress in understanding and addressing the immunological challenges of biologic development. We look forward to seeing you in Lisbon!